🔗 Share this article

Given that the United States proceeds with unprecedented adjustments to its immunization schedules, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccinations during the global health crisis and has focused upon potential deaths following COVID-19 vaccination in her recent time at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Schedule

Health officials planned to announce sweeping revisions to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s national calendar, it is understood – a major change that would place the US out of step with many the world with insufficient data for improved outcomes. The planned update has been delayed until the new year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to speak at the event. She was newly appointed interim head of the FDA’s CDER, the fifth individual to head the center this year.

A Shift at the Agency

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon rolling back previously authorized immunizations at the FDA.

The new acting director has repeatedly called for discontinuing some pediatric immunization guidelines in the US in order to be more in line with the Danish model, a country with comprehensive healthcare and a population about the size of Wisconsin’s.

To date public appearances, she has kept her attention on vaccines – typically the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Expertise

Dr. Høeg has no obvious experience in medication creation, regulation or management, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since March.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, said Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a major agency. She lacks background in industry regulation.”

Former heads of CBER would “grasp laws and regulations and the science of drug development”, commented a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that prior appointees who ran CBER have had.”

This division has an immense workload at the agency, the former commissioner stated.

“The public just zeroes in on the novel medication approvals, but the generic program clears a multitude of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and so forth, and all of those have to be looked after,” she explained. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a significant administrative component to the job, which manages in excess of 5,000 personnel. “It’s a massive management job, if you perform it correctly,” she concluded.

Agency Reaction and Contentious Initiatives

Regarding concerns about Dr. Høeg's fitness for the role and whether this appointment signifies more teamwork among regulatory chiefs on immunizations, a spokesperson responded that the “questions are based on incorrect presumptions”.

“Her resume is consistent with the functions of her position,” the official said, citing the months Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a disputed expedited medication authorization process that apparently concerned her predecessors. “How are these therapies being selected for this expedited pathway? Who makes the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the regulatory body right now.”

Overall, he remarked, “the FDA seems to be moving towards less stringent oversight of pharmaceuticals, with the exception of immunizations.”

Documented Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if problematic, track record, some experts have noted. She published a analysis using non-validated volunteer-provided data to estimate the incidence of heart inflammation following Covid vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the new government included changing regulations for novel immunizations and ending “optional” vaccines, she remarked post-election on a podcast. At the agency, Dr. Høeg has according to sources suggested excluding teenage boys from receiving COVID-19 vaccinations.

“She is an complete dogmatist who starts off with her conclusions and reverse-engineers to fit the science in a extremely disingenuous, fraudulent manner,” Howard argued.

Taking Control and a “Revenge Tour”

Høeg joined fellow skeptics, {like|